Friday, July 17, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

Placebo

Phase 3 · small molecule · Multiple Sclerosis, Remittent Progressive

Placebo for Multiple Sclerosis, Remittent Progressive is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Phase 3 small molecule completed

Internal code 218MS304

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Phase 3
Modality
small_molecule
Indication
Multiple Sclerosis, Remittent Progressive
Status
completed
Trials
1

Clinical trials